易瑞生物(300942) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥100,582,552, representing an increase of 83.18% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥32,352,658.58, a significant increase of 155.13% year-over-year[3]. - The net profit excluding non-recurring gains and losses was ¥29,166,302.65, up 206.59% from the previous year[3]. - The basic earnings per share (EPS) was ¥0.0807, reflecting a growth of 129.26% compared to the same quarter last year[3]. - The company achieved operating revenue of CNY 431.07 million for the first three quarters of 2021, representing a year-on-year growth of 131.15%[14]. - The net profit attributable to shareholders reached CNY 195.66 million, a year-on-year increase of 277.03%[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 178.01 million, up 295.30% year-on-year[14]. - Total operating revenue for Q3 2021 reached ¥431,072,994.36, a significant increase of 131.3% compared to ¥186,494,430.62 in Q3 2020[21]. - Operating profit for Q3 2021 was ¥224,027,270.13, up from ¥58,981,752.58 in the same period last year, reflecting a growth of 278.5%[22]. - Net profit for Q3 2021 amounted to ¥195,631,959.45, compared to ¥51,909,188.28 in Q3 2020, representing an increase of 276.5%[22]. - The total comprehensive income for the period was CNY 194,894,966.29, compared to CNY 51,816,554.12 in Q3 2020, marking an increase of about 275.5%[23]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,107,073,439.24, an increase of 69.57% from the end of the previous year[3]. - Total current assets as of September 30, 2021, were ¥896,503,395.57, up from ¥526,129,020.88 at the end of 2020, indicating a growth of 70.3%[18]. - Total assets reached ¥1,107,073,439.24 as of September 30, 2021, compared to ¥652,886,483.47 at the end of 2020, marking an increase of 69.5%[19]. - Total liabilities increased to ¥205,909,931.81 in Q3 2021 from ¥103,903,179.01 in Q3 2020, reflecting a growth of 97.8%[19]. - Total liabilities reached CNY 103,903,179.01, with non-current liabilities at CNY 25,783,875.37[30]. - Current liabilities totaled CNY 78,119,303.64, with accounts payable at CNY 14,644,174.02[29]. - The total liabilities and owner's equity combined amounted to CNY 652,886,483.47[30]. Cash Flow - Cash flow from operating activities for the year-to-date reached ¥200,984,268.99, showing a remarkable increase of 417.19%[3]. - Net cash flow from operating activities was CNY 200,984,268.99, compared to CNY 38,861,074.17 in Q3 2020, indicating a growth of over 416%[26]. - The company reported a net cash outflow from investing activities of CNY -488,920,887.28, compared to CNY -354,702,861.41 in the same period last year[26]. - Cash inflow from financing activities was CNY 195,740,100.00, significantly higher than CNY 22,000,000.00 in Q3 2020[26]. - The company paid CNY 18,038,700.00 in dividends and interest, down from CNY 45,354,479.33 in the previous year[26]. Research and Development - Research and development expenses for Q3 2021 were ¥45,738,147.09, compared to ¥30,478,620.64 in Q3 2020, an increase of 50.0%[22]. - The company added 6 new authorized patents during the reporting period, including 1 invention patent[15]. Regulatory and Compliance - The company participated in the formulation of the national standard for "Immunochromatographic Test Strip Detection General Principles," which was approved and published[15]. - The company obtained a Class III medical device registration certificate for the HIV antibody test kit (colloidal gold method) in domestic registration[15]. - The company secured over 40 new EU CE certifications for international registration during the reporting period[15]. - The company has implemented new leasing standards affecting the financial statements, indicating a proactive approach to compliance and financial management[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 15,707[10]. - The company launched a restricted stock incentive plan draft in 2021 to enhance its incentive mechanism and support high-quality development[15]. - The company was included in the third batch of "specialized and innovative" small giant enterprises by the Ministry of Industry and Information Technology, indicating recognition of its advanced technology and business expansion[14]. Other Financial Metrics - The weighted average return on equity (ROE) improved to 3.65%, an increase of 1.25% year-over-year[3]. - The company reported a decrease in other comprehensive income, with a net amount of -¥766,404.59 in Q3 2021 compared to -¥78,983.41 in Q3 2020[22]. - The company recognized a right-of-use asset increase of CNY 44,711,437.99 due to the new leasing standard[30]. - The report for the third quarter was not audited[31].